54 related articles for article (PubMed ID: 38609739)
1. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Hernando J; Roca-Herrera M; García-Álvarez A; Raymond E; Ruszniewski P; Kulke MH; Grande E; García-Carbonero R; Castellano D; Salazar R; Ibrahim T; Teule A; Alonso V; Fazio N; Valle JW; Tafuto S; Carmona A; Navarro V; Capdevila J
Eur J Cancer; 2023 Jul; 188():39-48. PubMed ID: 37196483
[TBL] [Abstract][Full Text] [Related]
2. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8].
Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
Eur J Cancer; 2019 Sep; 119():198. PubMed ID: 31375258
[No Abstract] [Full Text] [Related]
4. Matching-adjusted indirect treatment comparison of [
Khan MS; Stamp E; Sammon C; Brabander T; de Herder WW; Pavel ME
EJC Suppl; 2021 Nov; 16():5-13. PubMed ID: 34912478
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48].
Hernando J; Roca-Herrera M; García-Álvarez A; Raymond E; Ruszniewski P; Kulke MH; Grande E; Carbonero RG; Castellano D; Salazar R; Ibrahim T; Teule A; Alonso V; Fazio N; Valle JW; Tafuto S; Carmona A; Navarro V; Capdevila J
Eur J Cancer; 2024 May; 203():114061. PubMed ID: 38609739
[No Abstract] [Full Text] [Related]
6. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
7. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours.
Strosberg JR; Kvols LK
Expert Opin Investig Drugs; 2007 Feb; 16(2):219-24. PubMed ID: 17243941
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Fraenkel M; Kim MK; Faggiano A; Valk GD
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
[TBL] [Abstract][Full Text] [Related]
11. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
